Skip to main content
. 2021 Sep 27;44(9):658–669. doi: 10.14348/molcells.2021.0173

Fig. 5. Two putative eRNAs and their validated mRNA targets involved in patient survival.

Fig. 5

(A and B) Heat map of the putative target mRNAs overlapping with the lists of the two eRNA KD experiments: (A) putative target mRNAs overlapping with the list of DEGs generated in the THUMPD3-AS1 KD experiment and (B) putative target mRNAs overlapping with the list of DEGs generated in the LINC01572 KD experiment. NC, negative control; TH-KD, THUMPD3-AS1 KD; L01572-KD, LINC01572 KD. (C and D) Boxplots of the expression values of eRNAs and their target mRNAs estimated with the TCGA-LIHC dataset: (C) expression values of THUMPD3-AS1 and its target mRNAs and (D) expression values of LINC01572 and its target mRNAs. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. (E and F) Kaplan–Meier plots of the two eRNAs and their validated target mRNAs. Note that the validated target mRNAs were defined as those eRNA-target mRNA pairs that were confirmed in the analysis in (A-D); (A) and (C) show the THUMPD3-AS1 results, and (B) and (D) show the LINC01572 results. Survival analysis was performed using the clinical information of the TCGA-LIHC dataset (see Materials and Methods section). (G) Table of the hazard ratios (HR) and P values of each gene identified by Cox regression analysis.